Atlas Trials

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Clinical trial NCT04409314 · COMPLETED

Trial details

NCT number
NCT04409314
Sponsor
University of California, San Francisco
Status
COMPLETED
Study type
OBSERVATIONAL
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell LymphomaRecurrent Malignant NeoplasmRecurrent Plasma Cell MyelomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell LymphomaRefractory Malignant NeoplasmRefractory Plasma Cell MyelomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Start date
2020-04-16
Primary completion
2023-08-09
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.